Home > Insider Trading > Filing (0001555280-17-000132)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1555280	Zoetis Inc.	ZTS	Pharmaceutical Preparations (2834)	460696167

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1567826	A. Catherine Knupp	C/O Zoetis Inc. 10 Sylvan Way Parsippany NJ 07054	Executive Vice President	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2017-05-12	5,785	$60.16	24,415	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Phantom Stock Unit	Disposition	2017-05-12	14,813	$19.10	4,725	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	I	Direct

Footnotes

The Price reported in Table I, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.16 to $60.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
These phantom stock units, which were acquired pursuant to the Zoetis Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment fund at any time, provided Zoetis may limit the timing, frequency and permissibility of transfers from one investment fund to another at any time.
Each phantom stock unit represents a fraction of a phantom share of Zoetis common stock, plus a small amount of cash-equivalent investments (the cash-equivalent investments typically represent around 5% of the total value of the phantom stock unit). Accordingly, the value of each phantom stock unit is determined by reference to the market value of Zoetis common stock and the value of the cash-equivalent investments.